SKOKIE, Ill.--(BUSINESS WIRE)--Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, today announced that the company is scheduled to present at the 10th Annual Biotech Showcase conference held January 8-10, 2018 in San Francisco.
Dr. David Giljohann, Chief Executive Officer of Exicure, will present a company overview on Tuesday, January 9th at 10:15 a.m. Pacific Time at the Hilton Union Square in San Francisco.
A live webcast of the presentation will be available on the Events & Presentations section of Exicure's website and will also be archived following the presentation.
About Exicure, Inc.
Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, Ill. www.exicuretx.com